Status:
COMPLETED
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®
Lead Sponsor:
Bio Products Laboratory
Conditions:
Primary Antibody Deficiency
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The primary objective was to determine the efficacy of Human Normal Immunoglobulin (Subgam®) given subcutaneously by weekly infusion to patients with primary antibody deficiency. The secondary object...
Eligibility Criteria
Inclusion
- The main criteria for inclusion in the study were as follows:
- A diagnosis of primary antibody deficiency;
- No lower or upper age limit (any age was eligible);
- With stable disease and receiving immunoglobulin (IVIG or SCIG) therapy for at least six months prior to starting the study;
- Written informed consent (patient/parent/guardian).
Exclusion
- \-
Key Trial Info
Start Date :
June 1 2000
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02247141
Start Date
June 1 2000
Last Update
January 24 2018
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Papworth Hospital
Papworth Everard, Cambridgeshire, United Kingdom
2
Royal Preston Hospital
Preston, Lancashire, United Kingdom
3
Guest Hospital
Dudley, West Midlands, United Kingdom
4
Birmingham Children's Hospital
Birmingham, United Kingdom